Pharmaceutical research company Pharmaxis (ASX:PXS)
has announced it has achieved extended reimbursement of its cystic fibrosis drug on the government’s Pharmaceutical Benefits Scheme (PBS).
Pharmaxis CEO Gary Phillips said the PSB extension of the locally developed and manufactured product will give more Australians with cystic fibrosis access to treatment.
The reimbursement of the company’s drug Bronchitol is in conjunction with another cystic fibrosis medication (Pulmozyme) used together as part of a treatment regime.
Bronchitol is a portable inhaler used as an additional treatment for the incurable genetic condition which affects one in every 2500 infants.
The drug which is deemed appropriate for patients over the age of six has been studied in more than 1000 clinical trial patients and has the support of the healthcare community.